Vaccinex, Inc. Announces 1-For-15 Reverse Stock Split
Vaccinex, Inc., (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will